Expertise in
13
conditions

Dr. Daniel Soteres

Allergy and Immunology
7608 N Union Blvd Ste D, 
Colorado Springs, CO 
On Staff At
Accepting New Patients
Expertise in
13
conditions
7608 N Union Blvd Ste D, 
Colorado Springs, CO 

Overview

Daniel Soteres is an Allergy and Immunologist in Colorado Springs, Colorado. Dr. Soteres is highly rated in 13 conditions, according to our data. His top areas of expertise are Angioedema, Hereditary Angioedema, Hives, and Sinusitis. Dr. Soteres is currently accepting new patients.

His clinical research consists of co-authoring 26 peer reviewed articles and participating in 15 clinical trials. MediFind looks at clinical research from the past 15 years.

Graduate Institution

Tulane University School Of Medicine

Residency

Tulane University Hospital Clinic

Specialties

Allergy and Immunology

Licenses

Allergy & Immunology in CO

Board Certifications

American Board Of Allergy And Immunology

Fellowships

Tulane University Hops and Clinics

Hospital Affiliations

Uch-Memorial Health System

Languages Spoken

English

Gender

Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Aetna
  • EPO
  • HMO
  • POS
  • PPO
Anthem BCBS
  • EPO
  • HMO
  • POS
  • PPO
Blue Cross Blue Shield
  • EPO
  • HMO
  • POS
  • PPO
Blue Shield of California
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE-MEDICAID PLAN
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
  • PPO
Cambia Health Solutions
  • EPO
  • INSURANCE PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • PPO
CareFirst
  • HMO
  • POS
  • PPO
Change Healthcare
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
Cigna
  • EPO
  • HMO
  • PPO
Community Health
  • EPO
  • HMO
Devoted Health
  • MEDICARE MAPD
  • OTHER MEDICARE
Freedom Life
  • INSURANCE PLAN
Health Care Services Corporation
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
  • PPO
HealthPartners
  • POS
  • PPO
Highmark
  • EPO
  • HMO
  • PPO
Horizon Healthcare
  • EPO
  • POS
Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
Kaiser Permanente
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • OTHER MEDICARE
  • POS
  • PPO
Medicaid
  • OTHER MEDICAID
  • STATE MEDICAID
Premera Blue Cross
  • INSURANCE PLAN
  • MEDICARE MAPD
  • OTHER COMMERCIAL
  • PPO
SelectHealth
  • HMO
  • POS
TeamCare
  • OTHER COMMERCIAL
Trustmark
  • PPO
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO
Walgreens
  • MEDICARE DISCOUNT CARD
  • MEDICARE PDP
  • OTHER MEDICARE
Wellcare
  • EPO
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
View 20 Less Insurance Carriers -

Locations

Asthma And Allergy Associates Pc
7608 N Union Blvd Ste D, Colorado Springs, CO 80920
Other Locations
Asthma And Allergy Associates Pc
2709 N Tejon St, Colorado Springs, CO 80907
Asthma And Allergy Associates Pc
595 Chapel Hills Dr Ste 240, Colorado Springs, CO 80920
Asthma And Allergy Associates Pc
517 Colorado Ave, Pueblo, CO 81004

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

14 Clinical Trials

A Long-term Study to Assess the Safety and Efficacy of Lebrikizumab in Patients With Moderate-to-Severe Atopic Dermatitis (ADjoin)
A Long-term Study to Assess the Safety and Efficacy of Lebrikizumab in Patients With Moderate-to-Severe Atopic Dermatitis (ADjoin)
Enrollment Status: Completed
Publish Date: November 05, 2025
Intervention Type: Biological
Study Drug: Lebrikizumab
Study Phase: Phase 3
A Longitudinal Observational Study of Patients With Chronic Disease
A Longitudinal Observational Study of Patients With Chronic Disease
Enrollment Status: Terminated
Publish Date: April 03, 2025
A Phase 3, Multicenter, Open-label Continuation Study With Budesonide Oral Suspension (BOS) for Adolescent and Adult Subjects With Eosinophilic Esophagitis (EoE)
A Phase 3, Multicenter, Open-label Continuation Study With Budesonide Oral Suspension (BOS) for Adolescent and Adult Subjects With Eosinophilic Esophagitis (EoE)
Enrollment Status: Terminated
Publish Date: February 19, 2025
Intervention Type: Drug
Study Drug: Budesonide oral suspension
Study Phase: Phase 3
A Phase 3, Multicenter, Double-blind Extension Study to Evaluate Maintenance of Efficacy of Oral Budesonide Suspension (OBS) and Long-term Treatment Effect of OBS in Adolescent and Adult Subjects (11 to 55 Years of Age, Inclusive) With Eosinophilic Esophagitis (EoE)
A Phase 3, Multicenter, Double-blind Extension Study to Evaluate Maintenance of Efficacy of Oral Budesonide Suspension (OBS) and Long-term Treatment Effect of OBS in Adolescent and Adult Subjects (11 to 55 Years of Age, Inclusive) With Eosinophilic Esophagitis (EoE)
Enrollment Status: Completed
Publish Date: February 19, 2025
Intervention Type: Drug
Study Phase: Phase 3
Oral Budesonide Suspension (OBS) in Adolescent and Adult Subjects (11 to 55 Years of Age, Inclusive) With Eosinophilic Esophagitis: A Phase 3 Randomized, Double-blind, Placebo-controlled Study
Oral Budesonide Suspension (OBS) in Adolescent and Adult Subjects (11 to 55 Years of Age, Inclusive) With Eosinophilic Esophagitis: A Phase 3 Randomized, Double-blind, Placebo-controlled Study
Enrollment Status: Completed
Publish Date: February 19, 2025
Intervention Type: Drug
Study Phase: Phase 3
A Phase 3 Long-term Safety Extension Study of SHP647 in Subjects With Moderate to Severe Ulcerative Colitis or Crohn's Disease (AIDA)
A Phase 3 Long-term Safety Extension Study of SHP647 in Subjects With Moderate to Severe Ulcerative Colitis or Crohn's Disease (AIDA)
Enrollment Status: Completed
Publish Date: June 21, 2024
Intervention Type: Drug
Study Drug: Ontamalimab
Study Phase: Phase 3
An Open-Label Study to Evaluate the Long-Term Safety and Efficacy of Lanadelumab for Prevention Against Acute Attacks of Non-histaminergic Angioedema With Normal C1-Inhibitor (C1-INH)
An Open-Label Study to Evaluate the Long-Term Safety and Efficacy of Lanadelumab for Prevention Against Acute Attacks of Non-histaminergic Angioedema With Normal C1-Inhibitor (C1-INH)
Enrollment Status: Completed
Publish Date: June 17, 2024
Intervention Type: Drug
Study Drug: Lanadelumab
Study Phase: Phase 3
A Phase 3, Multicenter, Randomized, Placebo-controlled, Double-blind Study to Evaluate the Efficacy and Safety of Lanadelumab for Prevention Against Acute Attacks of Non-histaminergic Angioedema With Normal C1-Inhibitor (C1-INH)
A Phase 3, Multicenter, Randomized, Placebo-controlled, Double-blind Study to Evaluate the Efficacy and Safety of Lanadelumab for Prevention Against Acute Attacks of Non-histaminergic Angioedema With Normal C1-Inhibitor (C1-INH)
Enrollment Status: Completed
Publish Date: December 27, 2023
Intervention Type: Other, Drug
Study Drug: Lanadelumab
Study Phase: Phase 3
A Phase 3, 16-week, Randomized, Double-Blind, Placebo-Controlled, Parallel- Group Study to Assess the Impact of Lebrikizumab on Vaccine Responses in Adult Patients With Moderate-to-Severe Atopic Dermatitis
A Phase 3, 16-week, Randomized, Double-Blind, Placebo-Controlled, Parallel- Group Study to Assess the Impact of Lebrikizumab on Vaccine Responses in Adult Patients With Moderate-to-Severe Atopic Dermatitis
Enrollment Status: Completed
Publish Date: October 17, 2023
Intervention Type: Drug
Study Drug: Lebrikizumab
Study Phase: Phase 3
An Observational, Non-interventional, Study of Patients With Hereditary Angioedema in the United States and Canada (EMPOWER Study)
An Observational, Non-interventional, Study of Patients With Hereditary Angioedema in the United States and Canada (EMPOWER Study)
Enrollment Status: Completed
Publish Date: March 30, 2023
A Phase 3 Randomized, Double-blind, Placebo-controlled, Parallel-group Efficacy and Safety Study of SHP647 as Maintenance Therapy in Subjects With Moderate to Severe Crohn's Disease (CARMEN CD 307)
A Phase 3 Randomized, Double-blind, Placebo-controlled, Parallel-group Efficacy and Safety Study of SHP647 as Maintenance Therapy in Subjects With Moderate to Severe Crohn's Disease (CARMEN CD 307)
Enrollment Status: Terminated
Publish Date: March 31, 2022
Intervention Type: Drug, Other
Study Drug: Ontamalimab
Study Phase: Phase 3
A Phase 3 Randomized, Double-blind, Placebo-controlled, Parallel-group Efficacy and Safety Study of SHP647 as Maintenance Therapy in Subjects With Moderate to Severe Ulcerative Colitis (FIGARO UC 303)
A Phase 3 Randomized, Double-blind, Placebo-controlled, Parallel-group Efficacy and Safety Study of SHP647 as Maintenance Therapy in Subjects With Moderate to Severe Ulcerative Colitis (FIGARO UC 303)
Enrollment Status: Completed
Publish Date: January 14, 2022
Intervention Type: Other, Drug
Study Phase: Phase 3
A Phase 3 Randomized, Double-blind, Placebo-controlled, Parallel-group Efficacy and Safety Study of SHP647 as Induction Therapy in Subjects With Moderate to Severe Ulcerative Colitis (FIGARO UC 301)
A Phase 3 Randomized, Double-blind, Placebo-controlled, Parallel-group Efficacy and Safety Study of SHP647 as Induction Therapy in Subjects With Moderate to Severe Ulcerative Colitis (FIGARO UC 301)
Enrollment Status: Terminated
Publish Date: June 14, 2021
Intervention Type: Other, Drug
Study Phase: Phase 3
A Phase 3 Randomized, Double-blind, Placebo-controlled, Parallel-group Efficacy and Safety Study of SHP647 as Induction Therapy in Subjects With Moderate to Severe Crohn's Disease (CARMEN CD 305)
A Phase 3 Randomized, Double-blind, Placebo-controlled, Parallel-group Efficacy and Safety Study of SHP647 as Induction Therapy in Subjects With Moderate to Severe Crohn's Disease (CARMEN CD 305)
Enrollment Status: Terminated
Publish Date: April 29, 2021
Intervention Type: Other, Biological
Study Phase: Phase 3
View 13 Less Clinical Trials

26 Total Publications

Sebetralstat for On-Demand Treatment of Mucosal Hereditary Angioedema Attacks in KONFIDENT-S.
Sebetralstat for On-Demand Treatment of Mucosal Hereditary Angioedema Attacks in KONFIDENT-S.
Journal: Clinical and translational allergy
Published: July 31, 2025
Similar Doctors
Expertise in
8
conditions
Dr. Matthew Greenhawt
Allergy and Immunology
Expertise in
8
conditions
Dr. Matthew Greenhawt
Allergy and Immunology

Children's Hospital Colorado

13123 E 16th Ave, 
Aurora, CO 
 (60.2 miles away)
720-777-2575
Languages Spoken:
English
See accepted insurances

Matthew Greenhawt is an Allergy and Immunologist in Aurora, Colorado. Dr. Greenhawt is highly rated in 8 conditions, according to our data. His top areas of expertise are Anaphylaxis, Food Allergy, Asthma, and Eosinophilic Esophagitis.

Flavia C. Hoyte
Expertise in
18
conditions
Dr. Flavia C. Hoyte
Allergy and Immunology
Expertise in
18
conditions
Dr. Flavia C. Hoyte
Allergy and Immunology

National Jewish Health

1400 Jackson Street, Allergy And Immunology Dept, 
Denver, CO 
 (60.3 miles away)
303-388-4461
Experience:
21+ years
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

National Jewish Health. Dr. Hoyte is highly rated in 18 conditions, according to our data. Her top areas of expertise are Asthma, Chronic Eosinophilic Pneumonia, Simple Pulmonary Eosinophilia, and Eosinophilic Pneumonia.

Expertise in
6
conditions
Dr. David Fleischer
Allergy and Immunology
Expertise in
6
conditions
Dr. David Fleischer
Allergy and Immunology

Children's Hospital Colorado

13123 E 16th Ave, 
Aurora, CO 
 (60.2 miles away)
720-777-2575
Languages Spoken:
English
See accepted insurances

David Fleischer is an Allergy and Immunologist in Aurora, Colorado. Dr. Fleischer is highly rated in 6 conditions, according to our data. His top areas of expertise are Food Allergy, Anaphylaxis, Asthma, Eosinophilic Esophagitis, and Endoscopy.

Frequently Asked Questions about Dr. Daniel Soteres

How do I make an appointment with Dr. Daniel Soteres?

You can book an appointment with Dr. Daniel Soteres by calling their office at 719-476-0420. MediFind provides direct contact information so you can schedule visits, second opinions, or consultations without navigating third-party calendars.

Is Dr. Daniel Soteres a top-rated expert for Angioedema?

MediFind is an objective health platform that identifies experts based on real-world data. Dr. Daniel Soteres is classified as an Elite expert for Angioedema, meaning they are among the top experts in the country for this condition. This ranking is based on their volume of patients, published research, and peer connections.

What conditions does Dr. Daniel Soteres specialize in?

While Dr. Daniel Soteres is a Allergy and Immunology, they have specific expertise in Angioedema, Hereditary Angioedema, and Hives. MediFind analyzes a doctor's articles and referral patterns to identify their specific areas of focus within Allergy and Immunology.

Does Dr. Daniel Soteres participate in research or clinical trials?

Yes. Dr. Daniel Soteres has published 26 articles and abstracts on conditions like Angioedema. You can view a list of Dr. Daniel Soteres's latest peer-reviewed publications and clinical trial participation on their profile to see if they are active in new treatments.

Does Dr. Daniel Soteres accept my insurance?

Dr. Daniel Soteres accepts most major insurance plans, including Aetna and Anthem BCBS. We recommend calling the office directly at 719-476-0420 to verify that your specific plan is currently accepted before your visit.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Soteres's expertise for a condition
ConditionClose
View All 8 Advanced Conditions
View All 9 Experienced Conditions
Want to save this doctor for later?
Sign Up
Is this your doctor?
Find A Second Opinion
Not sure about your diagnosis?
Check Your Symptoms
 
 
 
 
Learn about our expert tiers
Learn More
Are you the provider on this profile?
Claim Profile